Nascent Biotech Has Entered into an Agreement to Perform Phase I Clinical Study for Brain Cancer
August 19, 2019 14:04 ET
|
Nascent Biotech, Inc.
Study Planned for Multiple Brain Cancer Types in Phase I Setting San Diego, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced they...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
July 29, 2019 08:00 ET
|
VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
June 04, 2019 08:00 ET
|
VBI Vaccines, Inc.
Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...
CCAB announces creation of new brain cancer therapeutic company, Empirica Therapeutics, as part of its strategy to advance new early-stage life sciences companies
February 20, 2019 10:30 ET
|
Centre for the Commercialization of Antibodies and Biologics
TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) today announced a license agreement with Empirica Therapeutics Inc. aimed at...
Candel Therapeutics Completes $28.7 Million Series B Financing
January 04, 2019 14:33 ET
|
Candel Therapeutics
Proceeds to Accelerate Enrollment of Phase 3 Localized Prostate Cancer Clinical Trial and to Advance Late Stage High-Grade Glioma Clinical Program Candel to Expand Clinical Trials in Other...
Oblato acquires all rights to glioblastoma drug from OMRF
October 29, 2018 11:21 ET
|
Oklahoma Medical Research Foundation
OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of...
National Brain Tumor Society Responds to the 2018 Cancer Progress Report to Congress and the American Public
September 13, 2018 16:59 ET
|
National Brain Tumor Society
Newton, MA , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Less than two weeks after the unfortunate passing of John McCain as a result of brain cancer, the just-released American Association for Cancer...
National Brain Tumor Society Brings Realities of Glioblastoma to Congress
May 18, 2018 16:57 ET
|
National Brain Tumor Society
Washington, D.C., May 18, 2018 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, held a congressional...
Angiochem's ANG1005 Shows Clinical Benefits and Prolonged Survival for Breast Cancer Patients With Brain Metastases
October 17, 2016 07:00 ET
|
Angiochem
MONTREAL, QC--(Marketwired - October 17, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, recently presented data...
Angiochem to Present at ESMO 2016 Congress
October 03, 2016 07:00 ET
|
Angiochem
MONTREAL, QC--(Marketwired - October 03, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make a...